Seegene to Participate in High Profile Panel on Companion Diagnostics at BIO-Europe 2012
(firmenpresse) - GAITHERSBURG, MD and SEOUL, KOREA -- (Marketwire) -- 11/07/12 -- Seegene Inc., (KOSDAQ: 096530) today announced that the company's Executive Vice President, David L. Dolinger, Ph.D., will participate in a high profile panel on companion diagnostics titled "" at , on November 12 in Hamburg, Germany.
Dolinger will be joined by fellow panelists Guy Greiveldinger, Director, BD&L and M&A, Novartis; Bruce Jordan, Senior International Product Manager, Roche Diagnostics; David de Graaf, CEO, Selventa; and moderator Toby Zaleski, Principal, Base Pair Group. BIO-Europe 2012 is the pre-eminent partnering meeting in the life science industry, attracting more than 3,000 executives who will engage in over 15,000 one-to-one partnering meetings.
"BIO-Europe 2012 is a great event to mark Seegene's strides into the companion diagnostic market. Seegene's advanced multiplex molecular diagnostic technologies are well suited to the development of new companion diagnostics tests that can effectively guide personalized therapeutic decision-making," said Dolinger. "Our ability to simultaneously detect multiple analytes from limited patient samples, in a single test, creates diagnostics capable of identifying patients who can truly benefit from the new therapeutics. It also enables our pharmaceutical partners to effectively stratify patient populations for more successful clinical trials."
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ, and qTOCE™ -- are the foundation for M-MoDx tests that can simultaneously detect, differentiate and quantitate multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
For more information please visit or call +301-762-9066.
Contacts:
Sang-Kil Lee, Ph.D.
Seegene Inc.
301-762-9066
or
Constantine Theodoropulos
Base Pair Group
617-816-4637
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.11.2012 - 10:22 Uhr
Sprache: Deutsch
News-ID 1168261
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
GAITHERSBURG, MD and SEOUL, KOREA
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Seegene to Participate in High Profile Panel on Companion Diagnostics at BIO-Europe 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
Seegene (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
